Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms

Authors: Arianna Marinello, MD, Claudia Parisi, MD, Damien Vasseur, PhD, David Combarel, PharmD, Juliette Bihoreau, NP, Pernelle Lavaud, MD, Rémy Ezzedine, MD, Lodovica Zullo, MD, Luc Friboulet, PhD, Gerard Zalcman, MD, PhD, Antoine Italiano, MD, PhD, Benjamin Besse, MD, PhD, Mihaela Aldea, MD, PhD

Source: JTO Clinical and Research Reports, Vol 6, Iss 3, Pp 100773- (2025)

Subject Terms: EGFR-mutated NSCLC, RET fusion, BRAF V600E, Selpercatinib, Trametinib, Case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324001437; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/342ea336baed47408d1a5e3b6965bb2f